{"nctId":"NCT00560755","briefTitle":"Safety Study of ProQuad® rHA in Infants (V221-037)","startDateStruct":{"date":"2007-10-24","type":"ACTUAL"},"conditions":["Measles","Mumps","Rubella","Varicella"],"count":3388,"armGroups":[{"label":"ProQuad®","type":"EXPERIMENTAL","interventionNames":["Biological: ProQuad®"]}],"interventions":[{"name":"ProQuad®","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy subject of either gender,\n* Age from 12 to 22 months,\n* Negative clinical history of infection with measles, mumps, rubella, varicella or zoster,\n* Informed consent form signed by the parent(s) or by legal representative\n* Parent(s) or legal representative able to attend all schedule visits with the subject and to understand and comply with the study procedures\n\nExclusion Criteria:\n\n* Recent (≤ 3 days) history of febrile illness\n* Prior receipt of measles, mumps, rubella and/or varicella vaccination, either alone or in any combination\n* Recent (≤ 30 days) exposure to measles, mumps, rubella, varicella or zoster\n* Prior known sensitivity/allergy to any component of the vaccine\n* Severe chronic disease,\n* Blood dyscrasias, leukaemia, lymphomas of any type, or other malignant neoplasms affecting the haematopoietic and lymphatic system\n* Any severe thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injection\n* Humoral or cellular immunodeficiency,\n* Current immunosuppressive therapy\n* Family history of congenital or hereditary immunodeficiency\n* Hereditary problems of fructose intolerance\n* Known personal history of encephalopathy, seizure disorder or progressive, evolving or unstable neurological condition,\n* Known active tuberculosis\n* Recent (≤ 2 days) tuberculin test or scheduled tuberculin test through Visit 3\n* Receipt of immunoglobulins or blood-derived products in the past 150 days\n* Receipt of an inactivated vaccine in the past 14 days\n* Receipt of a live vaccine in the past 28 days\n* Any medical condition which, in the opinion of the investigator, might interfere with the evaluation of study objectives\n* Participation in another clinical study in the past 30 days","healthyVolunteers":true,"sex":"ALL","minimumAge":"12 Months","maximumAge":"22 Months","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Experiencing an Adverse Event (AE) After ProQuad® Dose 2","description":"The percentage of participants experiencing an AE(s) for up to 28 days after the second ProQuad® injection was determined.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.66","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Experiencing a Vaccine-related AE After ProQuad® Dose 2","description":"The percentage of participants experiencing a vaccine-related AEs for up to 28 days after the second ProQuad® injection was determined.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.77","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Experiencing a Solicited Injection-site AE After ProQuad® Dose 2","description":"The solicited injection-site AEs erythema, swelling, and pain were monitored for 4 days after administration of ProQuad® Dose 2.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.49","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Experiencing a Unsolicited Injection-site AE After ProQuad® Dose 2","description":"The percentage of participants experiencing a unsolicited injection-site AE(s) were monitored for up to 28 days after the second ProQuad® injection.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.65","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Experiencing a Injection-site Rash of Interest AE After ProQuad® Dose 2","description":"Injection-site rashes of interest, including measles-like, rubella-like, and vesicular, were monitored for up to 28 days after the second ProQuad® injection.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Experiencing a Systemic AE After ProQuad® Dose 2","description":"Systemic AEs were monitored for up to 28 days after the second ProQuad® injection.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.42","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Experiencing a Vaccine-related Systemic AE After ProQuad® Dose 2","description":"Vaccine-related systemic AEs were monitored for up to 28 days after the second ProQuad® injection.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.44","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Experiencing a Non-injection-site Rash of Interest AE After ProQuad® Dose 2","description":"Non-injection-site rashes of interest, including measles-like, rubella-like, varicella-like, and zoster-like rashes, were monitored for up to 28 days after the second ProQuad® injection.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Experiencing a Mumps-like Illness After ProQuad® Dose 2","description":"The percentage of participants experiencing a mumps-like illness for up to 28 days after the second ProQuad® injection was determined.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Experiencing a Serious AE (SAE) After ProQuad® Dose 2","description":"Serious AEs ere defined as any untoward consequence that results in death, is life-threatening, requires hospitalization or prolongs existing hospitalization, is a congenital anomaly/birth defect, or is any other medically important event.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.66","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Experiencing a Vaccine-related SAE After ProQuad® Dose 2","description":"Vaccine-related SAEs were defined as any untoward consequence that results in death, is life-threatening, requires hospitalization or prolongs existing hospitalization, is a congenital anomaly/birth defect, or is any other medically important event.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.21","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Experiencing a Solicited Injection-site AE After ProQuad® Dose 1","description":"The solicited injection-site AEs erythema, swelling, and pain were monitored for 4 days after administration of ProQuad® Dose 1.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.31","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Experiencing a Unsolicited Injection-site AE After ProQuad® Dose 1","description":"Unsolicited injection-site AEs were monitored for up to 28 days after the first ProQuad® injection.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.43","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With ≥ 1 Rectal Temperature Reading ≥ 38.0° C After ProQuad® Dose 1","description":"The percentage of participants with at least 1 rectal temperature reading ≥ 38.0° C was determined.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.10","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Experiencing a Systemic AE After ProQuad® Dose 1","description":"Systemic AEs were monitored for up to 28 days after the first ProQuad® injection.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.10","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":22,"n":3342},"commonTop":["Injection site erythema","Pyrexia","Injection site pain","Injection site swelling","Cough"]}}}